Workflow
Xtract One Selected to Support San Mateo Medical Center in Keeping Patients and Staff Secure
Globenewswire· 2025-06-24 11:00
SmartGateway Deployment Addresses California’s New Mandate for Hospital Weapons DetectionTORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its SmartGateway has been selected by San Mateo Medical Center, located in San Mateo, CA, to strengthen the facility’s security and provide AI-powered weapon detection. Xtract One’s leading technology-driven threat detection and security solutions are designed to enhance ...
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Globenewswire· 2025-06-24 11:00
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer- acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: ...
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
Globenewswire· 2025-06-24 11:00
Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to ...
Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction
Globenewswire· 2025-06-24 11:00
Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) ("Enzo" or the "Company") today announced that on June 23, 2025, following the market close, it entered into an Agreement and Plan of Merger (the "Merger Agreement") to be acquired by Battery Ventures, a global, technology-focused investment firm, through its newly formed entity Bethpage Parent, In ...
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Globenewswire· 2025-06-24 11:00
Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Approximately 16 subjects will be enrolled in the IOLITE study. The sample size was calculated based on the average symptomatic days per month and standard deviation data from subjects enrolled in the natural history study who would be otherwise eligible for IOLITE and provides 90% power to detect an effect size of at least 25%, allowing for a dropout rate up to 20%. Enrolled patients will initially receive either a sin ...
Tilray Medical Receives Italy’s First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use
Globenewswire· 2025-06-24 11:00
SAVONA, Italy, June 24, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced a significant milestone in its European expansion with the introduction of three new medical cannabis flower varieties in Italy. Through its wholly-owned subsidiary, FL Group, Tilray ...
The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
Globenewswire· 2025-06-24 11:00
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that it has completed the U.S. Food and Drug Administration's (FDA) Plant Biotechnology Consultation Program for its altered lignin alfalfa trait with the FDA notifying Cibus that it has no further questions concerning the use of altered lignin alfalfa in food or feed. This press release contains "forward ...
Rocky Shore Initiates Summer Program at Gold Anchor Project, Newfoundland
Globenewswire· 2025-06-24 11:00
Ken Lapierre, President and Chief Executive Officer, commented, "We are delighted to kick-start the summer field season at Gold Anchor. The program will include detailed till sampling, prospecting, geological and geophysical work at its Lane Pond Gold Target and other high-priority gold targets in the vicinity. At Lane Pond, significant gold values have been found in recent and historical sampling in an area 6,000 metres long and located proximal to the Appleton Fault. The Appleton Fault is the most prolifi ...
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
Globenewswire· 2025-06-24 11:00
REDWOOD CITY, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has partnered with Royalty Pharma on $2 billion in flexible funding to support Revolution Medicines' independent global development and commercialization strategy and operations. Revolution Medicines retains full strategic and executional control of product development and commer ...
Macerich Acquires Market-Dominant Crabtree Mall in Raleigh, NC for $290 million
Globenewswire· 2025-06-24 11:00
Attractive Initial Yield of Approximately 11% with Upside and is Accretive to Path Forward Plan The largest mall in North Carolina's high-growth Research Triangle area at 1,346,658 square feet, Crabtree today features over 200 total tenants and is anchored by Belk and Macy's. Crabtree currently generates $429 million in annual sales, $951 in sales per square foot and over 8.7 million annual visitors. About Macerich SANTA MONICA, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) (the ...